- United Kingdom
- /
- Healthtech
- /
- AIM:CRW
Craneware plc's (LON:CRW) Business Is Yet to Catch Up With Its Share Price
When close to half the companies in the Healthcare Services industry in the United Kingdom have price-to-sales ratios (or "P/S") below 3.2x, you may consider Craneware plc (LON:CRW) as a stock to potentially avoid with its 5x P/S ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the elevated P/S.
See our latest analysis for Craneware
How Has Craneware Performed Recently?
Recent revenue growth for Craneware has been in line with the industry. Perhaps the market is expecting future revenue performance to improve, justifying the currently elevated P/S. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.
Want the full picture on analyst estimates for the company? Then our free report on Craneware will help you uncover what's on the horizon.How Is Craneware's Revenue Growth Trending?
The only time you'd be truly comfortable seeing a P/S as high as Craneware's is when the company's growth is on track to outshine the industry.
Taking a look back first, we see that the company managed to grow revenues by a handy 5.1% last year. Pleasingly, revenue has also lifted 143% in aggregate from three years ago, partly thanks to the last 12 months of growth. So we can start by confirming that the company has done a great job of growing revenues over that time.
Looking ahead now, revenue is anticipated to climb by 7.1% per annum during the coming three years according to the four analysts following the company. With the industry predicted to deliver 9.0% growth each year, the company is positioned for a comparable revenue result.
In light of this, it's curious that Craneware's P/S sits above the majority of other companies. It seems most investors are ignoring the fairly average growth expectations and are willing to pay up for exposure to the stock. These shareholders may be setting themselves up for disappointment if the P/S falls to levels more in line with the growth outlook.
What We Can Learn From Craneware's P/S?
Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
Given Craneware's future revenue forecasts are in line with the wider industry, the fact that it trades at an elevated P/S is somewhat surprising. The fact that the revenue figures aren't setting the world alight has us doubtful that the company's elevated P/S can be sustainable for the long term. Unless the company can jump ahead of the rest of the industry in the short-term, it'll be a challenge to maintain the share price at current levels.
Many other vital risk factors can be found on the company's balance sheet. You can assess many of the main risks through our free balance sheet analysis for Craneware with six simple checks.
If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:CRW
Craneware
Develops, licenses, and supports computer software for the healthcare industry in the United States.
Reasonable growth potential with proven track record.